ELUT vs ABT vs MDT vs BSX

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -49. 6% for Elutia Inc. (ELUT). Elutia Inc. (ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate Abbott Laboratories (ABT) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elutia Inc.

(ELUT) is the cheapest at 0. 8x versus Boston Scientific Corporation at 29. 2x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 51x versus Medtronic plc's 36. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: ABT returned +166. 6% versus ELUT's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 06β versus Medtronic plc's 0. 42β — meaning MDT is approximately -818% more volatile than ELUT relative to the S&P 500. On balance sheet safety, Elutia Inc. (ELUT) carries a lower debt/equity ratio of 27% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -49. 6% for Elutia Inc. (ELUT). On earnings-per-share growth, the picture is similar: Elutia Inc. grew EPS 169. 4% year-over-year, compared to 30. 8% for Medtronic plc. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus 13. 9% for Medtronic plc — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 51x versus Medtronic plc's 36. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 16. 7x for Boston Scientific Corporation — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

In this comparison, MDT (3.

6% yield), ABT (2. 5% yield) pay a dividend. ELUT, BSX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 5% yield, +166. 6% 10Y return). Both have compounded well over 10 years (ABT: +166. 6%, BSX: +143. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELUT is a small-cap deep-value stock; ABT is a mid-cap deep-value stock; MDT is a mid-cap income-oriented stock; BSX is a mid-cap high-growth stock. ABT, MDT pay a dividend while ELUT, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.